secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001437749-25-027725
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences publishes FIH data for nsPFA thyroid nodule treatment in Thyroid journal
--------------------------------------------------------------------------------

- Single-arm feasibility study by Prof. Spiezia at Ospedale del Mare, Naples, Italy; three cohorts.
- Fully treated nodules (Cohort 3) showed up to 93% size reduction at 1 year (avg 86%), symptom relief as early as 2 weeks.
- No intranodular fibrosis or scarring on follow-up ultrasounds.
- nsPFA achieved 71% volume reduction in 1 month vs RFA's typical 6-month timeline for comparable shrinkage.
- Publication in peer-reviewed journal Thyroid validates safety and effectiveness for benign nodules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925027725/0001437749-25-027725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925027725/plse20250825_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-027725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer